SQ-LIP-000016 · v1.3 (archived) · View current version →
Is gestrinone an effective treatment for lipedema?
Also asked as
- Does gestrinone work as a treatment for people with lipedema?
- How effective is gestrinone in managing lipedema symptoms?
- gestrinone lipedema treatment efficacy
- Can taking gestrinone improve lipedema outcomes?
- Current answer
- There is no clinical evidence that gestrinone is an effective treatment for lipedema.
- Knowledge state
- Evidence gap · Evidence confidence: very low (GRADE) · Stability: New · contested
- Evidence
- 0 supporting · 1 contradicting · 2 refining / context
- Main limitation
- No clinical studies of any design have evaluated gestrinone in lipedema patients, so efficacy and safety are entirely unknown; all support is mechanistic/theoretical and in vitro…
- Latest change
- Answer recompiled after human curation of the claim set. · v1.3
- Knowledge freshness
- 100% recent · current evidence base
- Last updated
- 2026-06-02 · v1.3
| Pain | not demonstrated | very_low (GRADE) | symptom-only |
| No clinical study evaluated gestrinone's effect on lipedema pain. | |||
| Limb volume / adipose burden | not demonstrated | very_low (GRADE) | disease-modifying |
| Only in vitro cell-viability data; no patient outcomes on fat reduction. | |||
| Quality of life | not demonstrated | very_low (GRADE) | symptom-only |
| No clinical data on quality-of-life outcomes. | |||
| Disease progression / modification | not demonstrated | very_low (GRADE) | disease-modifying |
| Mechanistic hypothesis only; no evidence of altering disease course. | |||
| Safety / complications | not demonstrated | very_low (GRADE) | symptom-only |
| Safety in lipedema, especially subcutaneous implants, is unstudied. | |||
Based on currently indexed evidence, there is no clinical evidence that gestrinone is an effective treatment for lipedema. A high-quality PRISMA systematic review (2025, high GRADE, low risk of bias) identified zero clinical trials, observational studies or case reports evaluating gestrinone for lipedema, particularly as subcutaneous implants — this is an absence of evidence, so its effectiveness and safety in lipedema patients remain unknown. Two narrative/mechanistic reviews (both very-low quality, risk of bias unknown) propose only a theoretical rationale: as a 19-nortestosterone progestin, gestrinone is hypothesized to act via PRβ to increase 17β-HSD2, inhibit 17β-HSD1 and aromatase, and thereby reduce local estradiol accumulation, ERα overactivation and adipogenesis in lipedema adipose tissue. However, these reviews provide only mechanistic hypotheses and in vitro cell-viability data (MTT in MDA-MB-231 and Huh7 cell lines) with NO clinical intervention data or patient outcomes; they offer theoretical context only and do not demonstrate efficacy on any clinical outcome (pain, limb volume, adipose tissue burden, quality of life or disease progression). Because no clinical evidence supports it, off-label use (notably via subcutaneous implants) is not justified, and the safety of that route is unstudied. The Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Lipedema Association oppose its use.
A synthesis rendered from the currently indexed evidence — versioned, not a verdict.
⚙ AI consolidation: Claude Opus 4.8 · 2026-06-02 — evidence-bounded; the AI does not opine
Answer recompiled after human curation of the claim set.
Knowledge freshness = share of the 3 indexed evidence sources from the last 5 years (newest 2025, oldest 2024) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
Supporting claims
- None indexed yet.
Contradictory claims
- SCR-LIP-000040 contradicting
There is no scientific evidence supporting gestrinone for lipedema: a PRISMA systematic review identified zero clinical trials, observational studies or case reports evaluating it, particularly as subcutaneous implants.
Lack of Scientific Evidence for the Use of Gestrinone in the Treatment of Lipedema: A Systematic Review — Amato et al. (2025)
Refining / context
- SCR-LIP-000328 context
This narrative review proposes, on a mechanistic/theoretical basis, that gestrinone (a 19-nortestosterone progestin acting via PRβ to increase 17β-HSD2 and inhibit 17β-HSD1 and aromatase) could reduce local estradiol accumulation and ERα overactivation in lipedema adipose tissue, but presents no clinical intervention data or outcomes in lipedema patients.
DOI:10.9734/jammr/2025/v37i25731 - SCR-LIP-000329 context
This review proposes a mechanistic rationale for gestrinone in lipedema—based on aromatase overexpression in lipedema adipose tissue, with gestrinone hypothesized to inhibit aromatase and block estrogen receptors and adipogenesis—but presents only in vitro cell-viability data (MTT in MDA-MB-231 and Huh7 lines) and no clinical trial demonstrating efficacy in lipedema patients.
DOI:10.3390/ph17091248
Major uncertainty
No clinical studies of any design have evaluated gestrinone in lipedema patients, so efficacy and safety are entirely unknown; all support is mechanistic/theoretical and in vitro, and whether the proposed hormonal pathway translates into any clinical benefit is undemonstrated.
Version history
- SQ-LIP-000016 · v1.3 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000016 · v1.2 — 2026-05-31 — This update added two very-low-quality narrative/mechanistic reviews proposing a theoretical rationale (aromatase/estrogen-pathway inhibition) and in vitro cell-viability data for gestrinone in lipedema, but these provide only theoretical context and do not change the absence of clinical efficacy evidence. · view this version
- SQ-LIP-000016 · v1.1 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000016 · v1.0 — 2026-05-30 — founding index (3 claims) · view this version
Key references
DOI:10.7759/cureus.97213 · DOI:10.9734/jammr/2025/v37i25731 · DOI:10.3390/ph17091248